key: cord-0727743-j0lb4xnw
authors: Kahn, Robin; Berg, Stefan; Berntson, Lillemor; Berthold, Elisabet; Brodin, Petter; Bäckström, Fredrik; Compagno, Michele; Fasth, Anders; Lingman Framme, Jenny; Horne, AnnaCarin; Hätting, Josefin; Król, Petra; Kukka, Antti J; Mossberg, Maria; Månsson, Bengt; Nordenhäll, Charlotta; Idring Nordström, Selma; Khammari Nyström, Fatine; Palmblad, Karin; Rasti, Reza; Rudolph, André; Rydenman, Karin; Sundberg, Erik; Säve‐Söderbergh, Eva; Altman, Maria
title: Population‐based study of multisystem inflammatory syndrome associated with COVID‐19 found that 36% of children had persistent symptoms
date: 2021-12-01
journal: Acta Paediatr
DOI: 10.1111/apa.16191
sha: 555739a46a68c119933be8794a8dcefca8c944be
doc_id: 727743
cord_uid: j0lb4xnw

AIM: Our aim was to describe the outcomes of multisystem inflammatory syndrome in children (MIS‐C) associated with COVID‐19. METHODS: This national, population‐based, longitudinal, multicentre study used Swedish data that were prospectively collected between 1 December 2020 and 31 May 2021. All patients met the World Health Organization criteria for MIS‐C. The outcomes 2 and 8 weeks after diagnosis are presented, and follow‐up protocols are suggested. RESULTS: We identified 152 cases, and 133 (87%) participated. When followed up 2 weeks after MIS‐C was diagnosed, 43% of the 119 patients had abnormal results, including complete blood cell counts, platelet counts, albumin levels, electrocardiograms and echocardiograms. After 8 weeks, 36% of 89 had an abnormal patient history, but clinical findings were uncommon. Echocardiogram results were abnormal in 5% of 67, and the most common complaint was fatigue. Older children and those who received intensive care were more likely to report symptoms and have abnormal cardiac results. CONCLUSION: More than a third (36%) of the patients had persistent symptoms 8 weeks after MIS‐C, and 5% had abnormal echocardiograms. Older age and higher levels of initial care appeared to be risk factors. Structured follow‐up visits are important after MIS‐C.

In April 2020, reports from several countries warned of the increased frequency of a hyperinflammatory condition, which had affected children who had contracted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1, 2 The condition was named multisystem inflammatory syndrome in children (MIS-C), and it has been defined by the World Health Organization. In short, affected children or adolescents must have fever, symptoms and laboratory features suggesting MIS-C and a history of SARS-CoV-2 infection.

Other disorders must be excluded. 3 The complexity of the disease presentation and treatment strategies has been described in many publications, 4-7 but comprehensive reports on the long-term outcomes are lacking. 8, 9 The first follow-up studies of MIS-C patients were published in 2021. [10] [11] [12] All three studies were relatively small and represented a selection of MIS-C cases. Most patients achieved good resolution of their somatic symptoms. However, the most comprehensive study, of 46 patients, 10 demonstrated emotional or psychosocial stress, as well as reduced exercise capacity after 6 months. To our knowledge, no further evidence or experience has so far been presented on risk factors for organ-specific outcomes or how follow-up visits should be managed in terms of content and duration. This highlights the fundamental need for large, population-based, follow-up studies of children recovering from MIS-C.

The aim of this prospective, Swedish population-based, study was to present nationwide follow-up data at 2 and 8 weeks after a MIS-C diagnosis. In addition, we wanted to describe the patients' symptoms and clinical examinations at follow-up, by age-and care-level groups. These results could then be used to discuss the appropriate duration and content of MIS-C follow-up programmes.

This was a longitudinal prospective population-based multicentre study of Swedish children with MIS-C from 1 December 2020 to 31 May 2021. When the first Swedish cases emerged in May 2020, the Swedish Paediatric Rheumatology Association initiated biweekly national online meetings for physicians involved in the care of patients with MIS-C. The purpose of the meetings was to report on the incidence and to discuss the management and outcomes of patients affected by this new disease entity. To ensure complete national coverage, mandatory reporting of MIS-C cases to the Swedish Paediatric Rheumatology Registry (the Registry) was implemented as soon as cases started to emerge. The first Swedish clinical guidelines on the treatment and management of MIS-C were published in June 2020. 13 It was quickly recognised that patients with MIS-C also needed to be seen after hospital discharge and national guidelines for structured follow-up visits were published in December 2020. 14 These recommended clinical assessments by physicians at 2 and 8 weeks and 6, 12, 18 and 24 months after a MIS-C diagnosis.

Heart examinations were recommended at 2 and 8 weeks and neuropsychiatric screening at 6 and 12 months.

By 31 May 2021, 243 Sweden cases of MIS-C had been reported to the Registry. All patients were under 18 years of age at diagnosis and fulfilled the World Health Organization case definition for MIS-C. The follow-up programme was not nationally standardised until 1 December 2020, and 66 patients diagnosed before this date were excluded from our study cohort. Oral and written consent was provided, so that the pseudonymised data of 152 of the 177 patients registered with MIS-C from 1 December 2020 to 31 May 2021 could be shared for research purposes. If the patient was under 15 years of age, this consent was provided by a parent or guardian ( Figure S1 ).

The electronic Registry contains prospectively collected data on Swedish cases of paediatric rheumatology diseases since 2009. 15 It can be connected to medical patient charts via the personal identity number that is issued to all Swedish residents at birth or immigration. 16 In 2020, a new custom-made interface was designed for the Registry so that all Swedish MIS-C cases could be entered, in order to create a population-based cohort for quality control and research purposes. In addition to including patients with MIS-C at baseline, it is mandatory to file a report for every outpatient visit after they are discharged.

A wide range of information was extracted from the Registry.

This included the baseline demographic data, the date of the MIS-C diagnosis and the results of the SARS-CoV-2 polymerase chain reaction test and serum immunoglobulin G antibodies to SARS-CoV-2.

It also included the level of care the patient received, namely outpatient, general ward, intensive care unit (ICU) or extracorporeal membrane oxygenation (ECMO) unit. The symptoms and signs at presentation that were extracted were as follows: fever, diarrhoea, vomiting, abdominal pain, lethargy, oedema, affected mucus membranes, dyspnoea, encephalopathy, seizures, irritability, nonpurulent conjunctivitis, scaly skin, reddened lips, headache, sore throat, cough, joint pain, lymphadenopathy and rashes. We also extracted electrocardiogram and echocardiogram results and laboratory results, namely the erythrocyte sedimentation rate (highest value before treatment in mm/h), albumin (lowest value in g/L), troponin I/T (highest value in ng/L) and N-terminal pro-brain natriuretic peptide (highest value in ng/L). Information was also collected from the Registry on the outpatient visits 2 and 8 weeks after diagnosis, including the dates of the visits and the patient history and complaints. The physical examination comprised the following: mouth and mucus membranes, lymph nodes on the throat and neck, heart auscultation, lung auscultation, blood pressure, palpation of the abdomen, skin and joints. The laboratory results were as follows: complete blood cell counts (n/10 9 /L), platelet counts (n/10 9 /L), albumin, ferritin (μg/L) D-dimers (mg/L) and fibrinogen equivalent units, electrocardiograms and echocardiograms. All the follow-up variables were categorised by the reporting physician as normal, abnormal or not examined. If the patient's history was described as abnormal, we collected the reported symptoms and signs.

An invitation to contribute patients to the study was issued to all Swedish paediatric clinics, and reminders were sent by email and discussed during regular online meetings, to avoid missed cases.

Data were prospectively collected in the Registry at the time of each follow-up visit. Time points at the follow-up visits varied slightly, according to the availability of slot times for the appointments. Visits that occurred 6-28 days after the MIS-C diagnosis were considered 2-week follow-up visits, and visits occurring at 6-12 weeks after diagnosis were considered 8-week visits. Due to practical and administrative reasons, 14 children had follow-up data at 8 weeks but not at 2 weeks. To avoid inter-user variability and measurement bias, the follow-up forms were short, predetermined and easy to fill in. This also minimised the amount of missing data and dropouts. 

We received responses from 14 of the 21 Swedish regions and these covered 152 patients, which was 75% of the paediatric patients diagnosed with MIS-C during the study period ( Figure S1 ). There were 19 patients (13%) with incomplete follow-up data at the date of the data extraction, and they were excluded from analyses ( Figure S1 ). The mean age of the remaining 133 patients (61% boys) was 9.3 years, and the children were divided into three age groups. Just over a quarter (28%) were aged 0-6 years, which is preschool age in Sweden, 45% were aged 7-12 years, and 27% were aged 13-18 years.

Baseline data from the initial hospitalisation are presented in Table 1 . During the acute phase, 36% of the patients tested positive for SARS-CoV-2 by polymerase chain reaction or antigen test and 80% tested positive for SARS-CoV-2 antibodies. The most common symptom at presentation was fever (99%), followed by abdominal pain (70%) and a rash (51%). An echocardiography was performed on 122 (92%) children during the acute phase, and 19% of these had decreased ejection fraction, and 16% had coronary artery involvement. Pericardial effusion and arrhythmia were less common. Most of the patients were cared for in a general paediatric ward and only 16% needed to be admitted to the ICU, including one who needed ECMO (Table 1 ).

There were 119 children who were followed up 2 weeks after their MIS-C diagnosis: 28% were 0-6 years old, 46% were 7-12 years old, and 26% were 13-18 years old. The physicians reported that 43% of the patient histories were abnormal, but clinical findings were uncommon. The exceptions were skin changes or rashes, which were seen in 15%. The most common abnormal laboratory results during these visits were the complete blood counts, platelet counts and albumin levels. Just under three-quarters (71%) of the patients underwent an electrocardiogram, and five (6%) of these were abnormal: one child aged 0-6 and four teenagers aged 13-18. In addition, 74% of the 119 children underwent an echocardiography and 14 (16%) of these were abnormal ( Table 2 ).

There were 89 children who were followed up 8 weeks after diagnosis: 27% were 0-6 years old, 48% were 7-12 years old, and 25% were 13-18 years old. The physicians reported that 36% of the patient histories were abnormal, but clinical findings were uncommon.

The exception was three teenagers who displayed abnormal findings during the joint examination. Abnormal growth was noted in six children aged 7-12 years. The most common abnormal laboratory values 8 weeks after MIS-C were the complete blood count and ferritin levels in general and abnormal platelet counts in 50% of the children aged 0-6. During this visit, 72% of the patients underwent an electrocardiogram and 2 (3%) of these were abnormal. In addition, 75% had an echocardiography and 3 (5%) of these were abnormal (Table 3) . These children had already presented with abnormal electrocardiogram or echocardiogra findings during the previous 2-week visit and no new cases presented during the 8-week visit ( Figure S2 ). (Table 4 ).

The severity of inflammation and multiorgan involvement seen in many children during the acute phase of MIS-C has raised concerns about persistent organ damage and long-term health effects. In this Swedish prospective nationwide population-based study, 133 children and teenagers with MIS-C were identified and described. symptoms, but nearly all of them had a normal physical examination.

The majority of the cohort had recovered, with no remaining symptoms or signs, 8 weeks after diagnosis. The most common complaint at that point was self-reported fatigue.

To our knowledge, only three previous reports have focused on the medium-to long-term outcomes of MIS-C. [10] [11] [12] All these studies concluded that their patients recovered well after MIS-C, despite being critically ill at the time of their initial admission.

Due to the relatively small sample sizes and clear findings at follow-up, questions about possible adverse outcomes have been raised. One study of 45 MIS-C patients from the USA followed up 31 of them at 1-4 months and 24 at 4-9 months after initial hospitalisation. 11 The authors reported that persistent immunological features were detected several months after diagnosis.

However, the only clinical data presented in that study were cardiological results and laboratory values. The most comprehensive multidisciplinary follow-up programme to be reported to date was from the Great Ormond Street Hospital for Children in the UK, 10 which followed up 46 patients with MIS-C 6 weeks and 6 months after diagnosis. The distribution of age and gender was similar to our study, but the disease severity was probably higher in the UK study, as 34.8% of the children were ventilated and only 15% of our cohort needed to be admitted to an ICU.

This was the most important difference between the UK study and ours. Our aim was to focus on a population-based study that included a range of very mild to severe cases and to develop a simple programme that colleagues across Sweden could use when they entered data on their MIS-C patients into the Registry. In contrast, the UK study focused on severe, but welldefined, cases that were followed, examined and assessed by a single multi-professional team.

There were some similarities in the results of our study and the UK study. The UK authors also concluded that most chil- of multiorgan failure, may be associated with a worse long-term outcome. Previous studies have not reported outcomes in relation to any measurements of disease severity. As an approximation of disease severity, we found that high levels of care seemed to be associated with a less favourable outcome 8 weeks after diagnosis.

It has been reported that cardiac symptoms and abnormal findings are common during the acute phase of MIS-C. 17, 18 In our cohort, 19% of the patients who underwent cardiac tests had reduced ejection fraction and 16% had abnormal coronary arteries during their hospital admission. The long-term effects on the heart are unknown, but have been discussed by other studies. 6, 19 Only three (5%) of the patients in our study who underwent cardiac tests had any echo- 

This population-based study adds to our understanding of the full disease spectra of MIS-C. We show that long-term symptoms 8 weeks after diagnosis were few and mild and that organic sequelae, including cardiac consequences, appeared to be rare. However, more than a third of the children reported symptoms at the 8-week follow-up and these need to be detected and addressed in all cases.

Age and the initial level of care may have influenced their long-term recovery. Regular follow-up visits after MIS-C are important, and we suggest that after 8 weeks, the focus should be on the patient history, including exercise and mental capacity and psychological well-being. Repeated assessments of cardiac function after normalisation at 8 weeks may not be required, but the long-term effects of MIS-C on cardiovascular health need to be more carefully evaluated.

The authors have no conflict of interest to declare. 

Hyperinflammatory shock in children during COVID-19 pandemic

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Available at: https:// www.WHO.int/news-room/comme ntari es/detai l/multi syste minfla mmato ry-syndr ome-in-child ren-and-adole scent s-with-covid

Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children

Treatment of multisystem inflammatory syndrome in children

A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process

Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19

Multisystem inflammatory syndrome in children: a systematic review

SARS-CoV-2 paediatric inflammatory syndrome. Paediatr Child Health (Oxford)

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study

longitudinal outcomes for multisystem inflammatory syndrome in children

Short-term outcomes in children recovered from multisystem inflammatory syndrome associated with SARS-CoV-2 infection

Covid-associated Hyperinflammation ALB

Nationella Riktlinjer För Uppföljning Av Multisystem Inflammatory Syndrome In Children (Mis-C) 2020. Available at

Available at: http://barnr eumar egist ret.se Accessed

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research

acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe

Review of cardiac involvement in multisystem inflammatory syndrome in children

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: version 2